$GNPX “Ultimate Stock Alerts” Genprex, Inc. Newsletter 7:38:44 AM May 4, 2021

on May 4, 2021 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "Ultimate Stock Alerts"

The following three charts can be used by potential investors to gauge the performance of "Ultimate Stock Alerts":


0 out of 2 campaigns closed down on first day


2 out of 2 campaigns closed up on first day


0 out of 2 campaigns had no net effect

GNPX Promotional Newsletter

The following is a newsletter released by "Ultimate Stock Alerts" promoting Genprex, Inc.


The following newsletter has not been verified for accuracy or completeness.


Don't Want Anymore Emails


New Alert Genprex, Inc. NASDAQ GNPX

GNPX has presented you with several incredible opportunities in the past that we have highlighted to you.

Following our last update in December, GNPX rallied from 4.10 to a high of 7.72 in February, experiencing upside of more than 88%.

Since then, GNPX has been consolidating, presenting what could be another opportunity.

Furthermore, the company has announced multiple developments recently that could be additional growth catalysts.

GNPX is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

The companys technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

GNPX works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

The companys lead product candidate, REQORSA quaratusugene ozeplasmid, is being evaluated as a treatment for non-small cell lung cancer NSCLC.

Sadly, each year, more people die of lung cancer than of colon, breast, and prostate cancers combined.

According to the American Cancer Society, lung cancer is by far the leading cause of cancer death among both men and women, making up almost 25% of all cancer deaths.

Non-small cell lung cancer NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses.

As the company further explains

REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells re-establish pathways for apoptosis, or programmed cell death, in cancer cells and modulate the immune response against cancer cells.

Furthermore, REQORSA has also been shown to block mechanisms that create drug resistance.

In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZenecas Tagrisso osimertinib for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

Since our last update, GNPX has announced multiple new developments

In January, the company announced

Genprex Achieves Major Manufacturing Milestone for REQORSA Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Here are the highlights from this press release

Company passes final release tests of scaled-up clinical grade production to supply drug product for upcoming Acclaim-1 and Acclaim-2 clinical trials in lung cancer

In February, the company announced

Genprex Issues Shareholder Letter and Provides Corporate Update

Here are the companys comments from this press release

We achieved many significant milestones in 2020 that have set the stage for a transformational 2021, said Rodney Varner, President and Chief Executive Officer of Genprex. The primary focus this past year was on the preparation for our two lead clinical trials in non-small cell lung cancer NSCLC. Our Acclaim-1 clinical trial will combine REQORSA with Tagrisso for patients with late stage NSCLC whose disease progressed after treatment with Tagrisso. Our Acclaim-2 clinical trial will combine REQORSA with Keytruda for NSCLC patients who are low expressors 1% to 49% of the protein programmed death-ligand 1 PD-L1. We remain on track to initiate both trials in the first-half of 2021. Additionally, the $40 million-plus in capital infusions in 2020 have provided us with a strong balance sheet as 2021 begins. We are grateful for the confidence and support of our shareholders and look forward to executing on our strategies to achieve a number of potentially value-creating milestones.

At the end of March, the company announced

Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting

As the company further explained in this press release

We look forward to the presentation of these data that highlight the potential of TUSC2 immunogene therapy to enhance chemo-immune combination treatments and overcome resistance to osimertinib in lung cancer, to an audience of the worlds leading cancer researchers, said Rodney Varner, President and Chief Executive Officer of Genprex. As lung cancer is the leading cause of cancer deaths worldwide, we remain keenly focused on initiating our Acclaim-1 and Acclaim-2 clinical trials to evaluate REQORSA, our proprietary TUSC2 immunogene therapy, in non-small cell lung cancer.

On April 12, the company announced

Genprex Collaborators Report Positive Preclinical Data for REQORSA Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

Here are the highlights from this press release

REQORSA Enhances Efficacy of Chemo-Immune Combination Therapy in KRAS-LKB1 Mutant NSCLC in Humanized Mice
REQORSA Overcomes Resistance to Targeted Therapy Osimertinib

In addition, most recently, the company announced

Genprex to Receive Inaugural License of the Year Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes

Here are the highlights from this press release

Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes

GNPX could be in a position to experience increased growth.

Make sure to do your own due diligence.

Sources , , , , , , , , , , , ,

Happy Trading


Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.



You should read and understand this disclaimer in its entirety before joining the website or emailblog list of UltimateStockAlerts.com the Publisher. The information collectively the Advertisement disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, andor losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission the SEC at www.sec.gov the Financial Industry Regulatory Authority the FINRA at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.govconsumercyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial andor legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

Owners and operators of the Publisher have been compensated twenty two thousand five hundred dollars by bank wire transfer on 42121 for the distribution of this advertisement about GNPX dated 5421. Previously, owners and operators of the Publisher have been compensated seventeen thousand five hundred dollars by bank wire transfer on 122120 for the distribution of a prior advertisement about GNPX. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 102920 for the distribution of a prior advertisement about GNPX. Previously, owners and operators of the Publisher have been compensated twenty two thousand five hundred dollars by bank wire transfer on 7820 for the distribution of a prior advertisement about GNPX. Previously, owners and operators of the Publisher have been compensated twelve thousand dollars by bank wire transfer on 6320 for the distribution of a prior advertisement about GNPX. Previously, owners and operators of the Publisher have been compensated fifteen thousand dollars by bank wire transfer on 42920 for the distribution of a prior advertisement about GNPX. Prior to this period, at the time of publication, we disclosed our compensation for the distribution of advertisements about GNPX. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.

You are receiving this reportrelease because you subscribed to receive it at our website or through a third-party site. All our newsletters include an unsubscribe link, and you can remove yourself at any time from our newsletters by clicking on that unsubscribe link. You can also contact us at infoUltimateStockAlerts.com to change your information at any time. By your subscription to our profiles, the viewing of this profile andor use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link

www.UltimateStockAlerts.comDisclaimer and www.UltimateStockAlerts.comPrivacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of 1 a client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.

Our records indicate that . requested and confirmed to be added to UltimateStockAlerts.com on January 26, 2015.

6020 Bent Pine Dr, Orlando, FL 32822, USA